Scorpion Therapeutics
Andy Jones has a diverse work experience in the pharmaceutical and biotech industry. Andy is currently working at Scorpion Therapeutics as the SVP - CMC Development. Prior to that, they held the role of Vice President - CMC Development at the same company. Before joining Scorpion Therapeutics, Andy worked at Johnson Matthey as the Global Director - Chemical Development and later as the Business Unit Director - New Product Introduction (API). Andy also served as the Pharmaceutical Process Development and Manufacturing Leader at the Bill & Melinda Gates Medical Research Institute. Andy has extensive consulting experience as the Principal at Pharma Consulting Associates, providing services in CMC, regulatory affairs, and quality systems. Andy has also held leadership positions at H3 Biomedicine, Concert Pharmaceuticals, Vertex Pharmaceuticals, Schering-Plough, Zeneca Pharmaceuticals, and ICI/Zeneca. Andy's expertise lies in pharmaceutical development, process chemistry, and CMC.
Andy Jones completed their education with a Post Doctoral Research in B.M. Trost at Stanford University from 1990 to 1992. Prior to that, they obtained a PhD in Chemistry under the guidance of Prof Colin W.G. Fishwick at the University of Leeds from 1987 to 1990. Andy began their higher education by earning a Natural Science (Hons) degree in Chemistry at King's College London from 1984 to 1987.
This person is not in any teams
Scorpion Therapeutics
1 followers
Scorpion Therapeutics was founded to expand the reach of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0, a pipeline of targeted small-molecule drugs that overcome the limitations of existing treatments.